Your selection

Innovation / 12.05.2026
Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.

1st Quarter 2026:

  • Sales of €72.9 million (previous year: €68.2 million)
  • EBIT before special items of €16.0 million (previous year: €16.2 million)
  • Net income of €10.4 Mio.  (previous year: €9.7 million)

 Forecast 2026:

  • Sales of around €320 million (confirmed)
  • EBIT before special items of around €80 million (confirmed) 
     

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year. Due to a slightly weaker product mix in the Isotope Products segment during the first two months of the year, adjusted Group EBIT decreased by 2% to €16.0 million. Net income increased by 7% to €10.4 million, or €0.17 per share.

Sales in the Medical segment were significantly higher in the first three months of the year at €41.5 million compared to the previous year (€34.4 million). The pharmaceutical radioisotope business remains the most important revenue driver. In particular, the development of sales of generators and in the Contract Manufacturing & Development (CDMO) segment is worth noting.

The Isotope Products segment generated sales of €31.5 million, which was €2.3 million, or approximately 7%, lower than in the first three months of the previous year. A strong fourth quarter of 2025 was followed by a subdued start to the year, which regained significant momentum in March.

The forecast for fiscal year 2026, published on 26 March 2026, remains unchanged. The Executive Board continues to anticipate revenue of approximately €320 million and adjusted EBIT of approximately €80 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q12026en
 

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Overview News

News Buch Berlin

Berlin honors outstanding deep-tech companies—including MyoPax

This year, for the first time, a Deep Tech Award was presented in the Bio & Health Tech category. The winner is MyoPax, a spin-off of the Max Delbrück Center and Charité.

more ...

Eckert & Ziegler Receives “Best Managed Companies Award” Once Again

Eckert & Ziegler SE (ISIN DE0005659700) has won the “Best Managed Companies Award” for the third time in a row. With this honor, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung, and the Federati...

more ...

Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year.

more ...

Events Buch Berlin

18.06.2026, 11:00
Einladung zum Tag der offenen Tür - „Room of Horror“ statt Langeweile

Die Akademie der Gesundheit e.V. öffnet am Campus Berlin-Buch ihre Tore und zeigt, dass Ausbildung auch „Room of Horror“, OP-Action und High-Tech-Simulation bedeuten kann.

more ...

19.06.2026, 18:30
Benefizkonzert für die Sanierung der barocken Schlosskirche Berlin-Buch

Magdalena Pflüger spielt Werke von Beethoven, Schumann, Rachmaninow und Schostakowitsch

more ...

20.06.2026, 14:00
Gauklerfest auf der Moorwiese

Der Archäologie- und Abenteuerspielplatz lädt wieder zum Gauklerfest ein

more ...

This website is supported by: